Fresenius Medical Care reported during an investor call May 3 that it now has 120,000 dialysis patients on Roche’s new anemia drug Mircera. That number exceeds the originally targeted 110,000 patients Fresenius had planned to have on the drug by the end of the first quarter and helped the company increase net income by 24% over the same quarter last year. The dialysis provider says about 155,000 of its 180,000 patients need drug therapy to treat their anemia.

Related: DOPPS Practice Monitor shows dialysis providers switching to Mircera, Aranesp